S. Strasser

发表

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.

R. Marinho, J. Dufour, P. Thuluvath, 2018, Journal of hepatology.

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders

B. Cowie, S. Lim, E. Gane, 2015, Gut.

Quality of life indicators in hepatic encephalopathy following supplementation with branched chain amino acids and/or synbiotics: A post‐hoc analysis

G. McCaughan, D. Bowen, N. Shackel, 2021 .

Hepatic artery stenosis after liver transplantation: Is endovascular treatment always necessary?

C. Pulitano, G. McCaughan, N. Shackel, 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Usage and outcomes of deceased donor liver allografts with preprocurement injury from blunt trauma

M. Sosef, S. Strasser, D. Verran, 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Prevalence and outcomes of Clostridioides difficile infection in liver transplant recipients

G. McCaughan, S. Strasser, A. Majumdar, 2021, Transplant infectious disease : an official journal of the Transplantation Society.

Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation

S. Strasser, D. Koorey, D. Verran, 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

V. Mazzaferro, P. Lamby, I. Bilbao, 2010, BMC Cancer.

Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.

M. Hellard, G. Ahlenstiel, G. Dore, 2020, Clinical Infectious Diseases.

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

P. Marcellin, K. Chayama, Sheng-Nan Lu, 2016, SpringerPlus.

Depot Pure GnRH Antagonist for Long-term Treatment of Ovarian Hyperthecosis Monitored by Multisteroid LCMS Profiling

David Handelsman, R. Desai, S. Strasser, 2021, Journal of the Endocrine Society.

Regulation of uridine diphosphate glucuronosyltransferase during the acute‐phase response

P. Desmond, S. Strasser, M. Mashford, 1998, Journal of gastroenterology and hepatology.

Iron overload in bone marrow transplant recipients

S. Strasser, G. Sale, K. Kowdley, 1998, Bone Marrow Transplantation.

Longterm outcome of the liver graft: A clinician's perspective—recurrent disease, the universal shifting

S. Strasser, 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?

H. Poustchi, J. George, G. Farrell, 2011, Hepatology.

Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation

G. McCaughan, S. Strasser, D. Koorey, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Emerging therapies for hepatitis C virus (HCV) infection: the importance of HCV genotype.

G. McCaughan, S. Strasser, 2000, Australian and New Zealand journal of medicine.

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

S. Sarin, A. Dokmeci, S. Hamid, 2021, Hepatology International.

Australian recommendations for the management of hepatocellular carcinoma

Stuart K. Roberts, J. Lubel, N. Shackel, 2021, The Medical journal of Australia.

Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients

T. Berg, P. Lampertico, H. Janssen, 2016, Alimentary pharmacology & therapeutics.

MELD-GRAIL and MELD-GRAIL-Na Are Not Superior to MELD or MELD-Na in Predicting Liver Transplant Waiting List Mortality at a Single-center Level

C. Pulitano, G. McCaughan, S. Strasser, 2022, Transplantation direct.

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

V. Mazzaferro, P. Lamby, I. Bilbao, 2015, Transplantation.

Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

P. Angus, V. Sundararajan, M. Sinclair, 2022, Alimentary pharmacology & therapeutics.

Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0

S. Barreto, John W. C. Chen, G. McCaughan, 2022, Cancers.

Palliative care in hepatocellular carcinoma

M. Cigolini, S. Strasser, Ken Liu, 2020, Journal of gastroenterology and hepatology.

Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection

P. Desmond, S. Strasser, K. Watson, 1995 .

Fulminant hepatic failure and liver transplantation.

J. Thompson, A. Sheil, G. McCaughan, 1992, Transplantation proceedings.

Managing hepatitis B to prevent liver cancer: recent advances

S. Strasser, 2014, Expert review of gastroenterology & hepatology.

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens

G. Gerken, K. Chayama, K. Reddy, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REV1TAL Study

G. Dore, P. Gow, S. Bollipo, 2017, Antiviral therapy.

Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review

S. Strasser, M. Berenguer, C. Vinaixa, 2017, Transplantation.

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis

A. Mangia, H. Wedemeyer, J. Calleja, 2015, PloS one.

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

M. Colombo, H. Wedemeyer, A. Streinu-Cercel, 2013, Gut.

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

G. Dore, S. Pol, A. Tran, 2013 .

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

M. Manns, V. de Lédinghen, E. Schiff, 2017, The New England journal of medicine.

Vitamin D replacement for cirrhosis-related bone disease

G. McCaughan, S. Strasser, E. Labio, 2006, Nature Clinical Practice Gastroenterology &Hepatology.

Reply to “Comments on the Editor Re: The Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation, Nutrients 2019, 11, 2097.”

M. Allman-Farinelli, G. McCaughan, D. Bowen, 2020, Nutrients.

Chronic graft‐versus‐host disease of the liver: Presentation as an acute hepatitis

M. Flowers, G. McDonald, S. Strasser, 2000, Hepatology.

Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study

M. Yuen, R. Hamatake, A. Bertoletti, 2021, JHEP reports : innovation in hepatology.

The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand

P. Gow, E. Gane, K. Stuart, 2022, Transplantation direct.

Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients

P. Saxena, G. McCaughan, S. Strasser, 2017, World journal of gastroenterology.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Manfred von der Ohe, A. Coates, C. Trautwein, 2019, The Lancet.

Clinical Cases in Hepatitis: Towards improving liver disease management in Australia

J. George, S. Strasser, S. Roberts, 2019, Journal of gastroenterology and hepatology.

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Z. Goodman, M. Stepanova, K. Kowdley, 2021, Hepatology communications.

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

V. Wong, T. Hassanein, I. Wapinski, 2020, Hepatology.

Early high peak hepatitis C viral load levels independently predict hepatitis C–related liver failure post–liver transplantation

G. McCaughan, N. Shackel, S. Strasser, 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Current perspectives in hepatitis C.

P. Desmond, S. Strasser, B. Smith, 1995, Australian and New Zealand journal of medicine.

Changes in hepatitis C‐related liver disease in a large clinic population

G. Ostapowicz, S. Bell, P. Desmond, 2001, Internal medicine journal.

Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement

J. Sasadeusz, H. Nandurkar, S. Strasser, 2019, The Medical journal of Australia.

Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray

R. Christopherson, J. George, L. Belov, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study

P. Gow, S. Bell, G. McCaughan, 2022, Hepatology International.

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension

M. Burroughs, J. Feld, S. Strasser, 2022, Infectious Diseases and Therapy.

Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center

S. Strasser, Andie S. Lee, Rebecca J. Davis, 2020, Transplant infectious disease : an official journal of the Transplantation Society.

Donor and recipient selection leads to good patient and graft outcomes for right lobe split transplantation versus whole graft liver transplantation in adult recipients

Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study

P. Gow, S. Bell, G. McCaughan, 2022, Hepatology International.

Turning the Tide on Hepatitis C Virus–Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand

P. Gow, E. Gane, K. Stuart, 2022 .

Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike

S. Strasser, Ken Liu, J. Chetwood, 2022, Hepatology International.

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

R. Talwani, S. Zeuzem, J. George, 2018, Journal of Gastroenterology.

University of Birmingham A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

A. Floreani, K. Kowdley, M. Trauner, 2016 .

Gastrointestinal and Hepatic Complications

G. McDonald, S. Strasser, 2007 .

Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10‐year follow‐up

K. Sullivan, B. Storer, M. Flowers, 1999, Hepatology.

Cirrhosis of the liver in long-term marrow transplant survivors.

K. Sullivan, B. Storer, G. McDonald, 1999, Blood.

Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease

E. Cvejic, M. Allman-Farinelli, G. McCaughan, 2018, Alimentary pharmacology & therapeutics.

Nutritional considerations in end‐stage liver disease

S. Strasser, H. Vidot, 2011, Journal of gastroenterology and hepatology.

The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research—Lessons in Scientific Community Outreach

J. MacLachlan, H. Drummer, C. Rodrigo, 2021, Viruses.

Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort

R. Leong, G. McCaughan, S. Strasser, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Title: Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. Short title: Epidemiology and outcomes of PSC with and without IBD in Australia Authors

R. Leong, G. McCaughan, S. Strasser, 2016 .

Hepatic Proteins in Regenerating Liver

Cs Lee, S. Strasser, P. Desmond, 1996 .

UDP-glucuronosyltransferase in the regenerating rat liver.

P. Desmond, S. Strasser, M. Mashford, 1996, Journal of gastroenterology and hepatology.

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

M. Buti, P. Marcellin, S. Lim, 2016, Gastroenterology.

Is there such a thing as protocol immunosuppression in liver transplantation?

G. McCaughan, S. Strasser, K. Sze, 2015, Expert review of gastroenterology & hepatology.

A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis

P. Angus, E. Gane, G. McCaughan, 2008, Hepatology.

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.

P. Angus, E. Gane, G. McCaughan, 2007, Gastroenterology.

Severe Hepatocellular Injury After Hematopoietic Cell Transplant: Incidence, Etiology, and Outcome

G. McDonald, S. Strasser, H. Shulman, 2009, Bone Marrow Transplantation.

Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome.

M. Thornquist, D. Hockenbery, G. McDonald, 2001 .

Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987–1997: incidence, causes, and outcome

M. Thornquist, D. Hockenbery, G. McDonald, 2001, American Journal of Gastroenterology.

Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management.

G. McDonald, S. Strasser, 1999, Blood.

Hepatitis virus infections in patients with cancer

G. Lau, G. McDonald, S. Strasser, 2003 .

Cholestasis after hematopoietic cell transplantation.

G. McDonald, S. Strasser, H. Shulman, 1999, Clinics in liver disease.

When should liver biopsy be performed after hematopoietic stem cell transplantation?

S. Strasser, 2008, Journal of gastroenterology and hepatology.

Feasibility, acceptability and safety of a nurse led hepatitis B clinic based in the community.

G. McCaughan, S. Strasser, J. Pritchard-Jones, 2015, Collegian.

Tenofovir-Associated Fanconi Syndrome in Patients with Chronic Hepatitis B Monoinfection

P. Snelling, S. Strasser, D. Gracey, 2013, Antiviral therapy.

Drugs in Development for the Treatment of Chronic Hepatitis B

S. Strasser, 2012, Current Hepatitis Reports.

Selective internal radiation therapy for hepatocellular carcinoma: A 15‐year multicenter Australian cohort study

C. Rogan, A. Zekry, M. Danta, 2022, Journal of gastroenterology and hepatology.

Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection

P. Desmond, S. Strasser, 1995, The Medical journal of Australia.

Liver transplantation for viral hepatitis.

G. McCaughan, S. Strasser, D. Koorey, 2005, Hospital medicine.

Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

P. Angus, P. Gow, J. George, 2018, Alimentary pharmacology & therapeutics.

Cryptococcal osteomyelitis of the skull in a liver transplant patient

G. Watson, S. Strasser, Ken Liu, 2016, Transplant infectious disease : an official journal of the Transplantation Society.

Hepatocellular carcinoma: current approaches to diagnosis and management

G. McCaughan, S. Strasser, D. Koorey, 2002, Internal medicine journal.

Pharmacotherapy of hepatocellular carcinoma

J. George, G. Farrell, G. McCaughan, 2003, Expert Opinion on Pharmacotherapy.

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

J. Reguła, F. Nevens, K. Lindor, 2016, The New England journal of medicine.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

V. Mazzaferro, L. Bassaganyas, J. Bruix, 2018, Gut.

Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma

T. Iseli, D. van der Poorten, J. George, 2016, PloS one.

Hypothalamic‐pituitary‐testicular function in end‐stage non‐alcoholic liver disease before and after liver transplantation

David Handelsman, G. McCaughan, S. Strasser, 1995, Clinical endocrinology.

Severe autoimmune hepatitis first presenting in the early post partum period.

S. Riordan, S. Strasser, D. Koorey, 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Therapies for chronic hepatitis B: emerging roles for nucleoside analogues.

G. McCaughan, S. Strasser, 2000, Australian and New Zealand journal of medicine.

Hepatitis B and Liver Transplantation

G. McCaughan, N. Shackel, S. Strasser, 2009 .

The Direct Cost of Managing Patients With Chronic Hepatitis B Infection in Australia

P. Gow, S. Strasser, S. Roberts, 2004, Journal of clinical gastroenterology.

Anti‐viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post‐partum flare

S. Locarnini, S. Strasser, D. Samarasinghe, 2014, Alimentary pharmacology & therapeutics.

Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen–positive liver transplant candidates

P. Angus, E. Gane, G. McCaughan, 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS

M. Buti, M. Sherman, S. Strasser, 2008 .

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

P. Angus, J. George, S. Locarnini, 2010, Gut.

HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis

V. Mazzaferro, P. Lamby, I. Bilbao, 2020, Transplant international : official journal of the European Society for Organ Transplantation.

A survey of Sydney general practitioners' management of patients with chronic hepatitis B

S. Liaw, B. Cowie, S. Strasser, 2016, The Medical journal of Australia.

Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders

P. Gow, G. McCaughan, K. Stuart, 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Long‐term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface‐antigen negative liver transplant recipients from hepatitis B core‐antibody‐positive donors

G. McCaughan, S. Strasser, D. Koorey, 2006, Clinical transplantation.

Immunity to vaccine-preventable viral infections in Australians being evaluated for liver transplantation.

S. Strasser, Ken Liu, Vikram Joshi, 2019, Transplantation.

Combination adefovir–lamivudine prevents emergence of adefovir resistance in lamivudine‐resistant hepatitis B

G. McCaughan, M. Ngu, S. Strasser, 2007, Journal of gastroenterology and hepatology.

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection

C. Stedman, K. Reddy, G. Dore, 2015, Annals of Internal Medicine.

Australian consensus recommendations for the management of hepatitis B

B. Cowie, J. MacLachlan, J. Lubel, 2022, The Medical journal of Australia.

HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon

T. Asselah, D. Ouzan, G. Kukolj, 2014 .

International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.

D. Samuel, N. Terrault, P. Kwo, 2017, Transplantation.

Five‐year efficacy and safety of tenofovir‐based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

P. Angus, J. George, S. Locarnini, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Tenofovir Rescue Therapy Achieves Long-Term Suppression of HBV Replication in Patients with Multi-Drug Resistant HBV: 4 Year Follow-Up of the TDF109 Cohort

P. Angus, J. George, S. Locarnini, 2012 .

Predictors of deferral of treatment for hepatitis C infection in Australian clinics

G. Dore, J. Amin, J. George, 2011, The Medical journal of Australia.

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B

M. Buti, P. Marcellin, R. Idilman, 2016, Alimentary pharmacology & therapeutics.

PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold

M. Yuen, D. Wong, R. Gish, 2019, Journal of Hepatology.

Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance.

S. O'toole, R. Saunderson, G. McCaughan, 2013, Journal of dermatological case reports.

Amanita phalloides poisoning and treatment with silibinin in the Australian Capital Territory and New South Wales

N. Buckley, D. Roberts, S. Strasser, 2013, The Medical journal of Australia.

mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.

V. Mazzaferro, I. Bilbao, U. Settmacher, 2020, Annals of surgery.

Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand.

A. House, P. Gow, J. McCall, 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis

P. Gow, J. George, G. McCaughan, 2020, Scandinavian journal of gastroenterology.

Passive transfer of nut allergy after liver transplantation.

T. Phan, S. Adelstein, G. McCaughan, 2003, Archives of internal medicine.

Immune checkpoint inhibitor-related hepatotoxicity: A review

S. Kao, S. Strasser, C. McKenzie, 2021, World journal of gastroenterology.

Patterns of Liver Allograft Rejection

G. McCaughan, D. Bowen, S. Strasser, 2021 .

Effect of ascites on bone density measurement in cirrhosis.

G. McCaughan, S. Strasser, E. Labio, 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.

D. Samuel, N. Terrault, P. Kwo, 2017, Transplantation.

Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index

J. Kench, G. McCaughan, N. Shackel, 2012, Journal of gastroenterology and hepatology.

Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: A comparison of complications and outcome

S. Strasser, R. Waugh, G. McCaughan, 1993, Journal of gastroenterology and hepatology.

protocolA prospective randomised , open-labeled , trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

V. Mazzaferro, P. Lamby, I. Bilbao, 2010 .

Management of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease

P. Angus, P. Gow, A. Testro, 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

P. Gow, A. Zekry, M. Weltman, 2019, Alimentary pharmacology & therapeutics.

Fever and Pancytopenia in a Liver Transplant Recipient: Going Against the Rules of Occam's Razor

S. Strasser, Rebecca J. Davis, L. Jackett, 2017, Transplantation direct.

POISE: A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England Journal of Medicine 2016, 375, 631-643

J. Reguła, F. Nevens, A. Floreani, 2016 .

Turning the Tide on Hepatitis C Virus–Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand

P. Gow, John W. C. Chen, E. Gane, 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy

P. Gow, A. Zekry, M. Weltman, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study

E. Cvejic, M. Allman-Farinelli, G. McCaughan, 2019, Nutrients.

Sclerosing peritonitis post liver transplantation: a rare condition where surgery is an important treatment option

G. McCaughan, S. Strasser, D. Verran, 2018, ANZ journal of surgery.

Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study

P. Chow, M. Kudo, Chien-Hung Chen, 2021, Journal of hepatocellular carcinoma.

Locoregional therapies for hepatocellular carcinoma: Which patients are most likely to gain a survival advantage?

G. McCaughan, S. Strasser, D. Koorey, 2010, Journal of gastroenterology and hepatology.

Isolated liver transplantation in children with cystic fibrosis – An Australian experience

E. O'Loughlin, P. V. van Asperen, G. McCaughan, 2010, Pediatric transplantation.

Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance

S. Chadban, C. Cheah, S. Strasser, 2021, HemaSphere.

The Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation

M. Allman-Farinelli, G. McCaughan, D. Bowen, 2019, Nutrients.

Hepatology Clinical

J. Kench, C. McKenzie, S. Strasser, 2018, Journal of Gastroenterology and Hepatology.

An update on the pathophysiology and management of polycystic liver disease

G. McCaughan, S. Strasser, M. Wong, 2017, Expert review of gastroenterology & hepatology.

Transforming Genes to Protect Against Liver Disease: Will siRNA-based Therapeutics Reduce the Need for Liver Transplantation?

S. Strasser, K. Waller, David G Bowen, 2023, Transplantation.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

V. de Lédinghen, G. Dore, S. Pol, 2015, Gastroenterology.

Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.

H. Wedemeyer, A. Streinu-Cercel, Christophe Moreno, 2014, Journal of hepatology.

Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting

R. Leong, G. McCaughan, M. Solomon, 2017, Expert review of gastroenterology & hepatology.

HIV, viral hepatitis and STIs: a guide for primary care

G. Dore, M. Kidd, S. Strasser, 2008 .

O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)

M. Buti, P. Marcellin, R. Idilman, 2015 .

Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: a multicenter, exploratory analysis.

S. Strasser, G. Sapisochin, P. Fontes, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Frailty in advanced liver disease

G. McCaughan, S. Strasser, A. Majumdar, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

P. Angus, S. Bollipo, A. Zekry, 2022, BMC Gastroenterology.

Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

P. Angus, S. Bollipo, A. Zekry, 2022, Digestive Diseases and Sciences.

A prospective audit of preprocedural fasting practices on a transplant ward: when fasting becomes starving.

N. Shackel, S. Strasser, S. Carey, 2016, Journal of clinical nursing.

Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

P. Angus, S. Bollipo, A. Zekry, 2022, Digestive Diseases and Sciences.

Sex Hormones Differentially Regulate Isoforms of UDP-Glucuronosyltransferase

P. Desmond, S. Strasser, M. Mashford, 1997, Pharmaceutical Research.

O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES – AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS

J. Reguła, F. Nevens, J. Drenth, 2014 .

International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.

D. Samuel, N. Terrault, P. Kwo, 2017, Transplantation.

International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.

D. Samuel, N. Terrault, P. Kwo, 2017, Transplantation.

The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand

P. Angus, M. Hellard, P. Gow, 2016, Journal of gastroenterology and hepatology.

Fatal late‐onset ornithine transcarbamylase deficiency after coronary artery bypass surgery

S. Strasser, B. Wilcken, B. Bennetts, 2007, The Medical journal of Australia.

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: Results of the first multicentre Australian trial

S. Strasser, R. Lin, M. Zimmerman, 1995 .

Adverse effects of modified release oxycodone/naloxone in patients with moderate to severe liver impairment

S. Strasser, V. Pattullo, G. Pattullo, 2018, The Medical journal of Australia.

Nonalcoholic fatty liver disease burden: Australia, 2019–2030

H. Razavi, J. George, S. Strasser, 2020, Journal of gastroenterology and hepatology.

Current approaches to the diagnosis and management of hepatocellular carcinoma

J. George, S. Strasser, J. F. Perry, 2005, Clinical and Experimental Medicine.

Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

G. Ahlenstiel, J. Zalcberg, C. Karapetis, 2022, Hepatology communications.

Ordering and interpreting hepatitis B serology

S. Strasser, S. Davison, 2014, BMJ : British Medical Journal.

Severe gastrointestinal bleeding after marrow transplantion, 1987–1997: Incidence, causes, and outcome

D. Hockenbery, G. McDonald, S. Strasser, 1998 .

Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review

G. McCaughan, S. Strasser, C. Sandroussi, 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation

J. Kench, C. Pulitano, G. McCaughan, 2022, Frontiers in Oncology.

Increasing liver transplantation waiting list mortality: a report from the Australian National Liver Transplantation Unit, Sydney

G. McCaughan, R. Allen, N. Shackel, 2010, Internal medicine journal.

Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma

J. Gamble, G. McCaughan, S. Strasser, 2023, JHEP reports : innovation in hepatology.

Australian recommendations for the management of hepatocellular carcinoma: a consensus statement

S. Clarke, D. Crawford, J. Lubel, 2020, The Medical journal of Australia.

Author reply

D. Bowen, N. Shackel, S. Strasser, 2013, Internal medicine journal.

Impact of Having a Planned Additional Operation at Time of Liver Transplant on Graft and Patient Outcomes

C. Pulitano, G. McCaughan, S. Strasser, 2020, Journal of clinical medicine.

Nonalcoholic fatty liver disease burden: Australia, 2019–2030

H. Razavi, J. George, S. Strasser, 2020, Journal of Gastroenterology and Hepatology.

Assessment of adult patients with chronic liver failure for liver transplantation in 2015: who and when?

G. McCaughan, N. Shackel, S. Strasser, 2016, Internal medicine journal.

adefovir dipivoxil in chronic hepatitis B following failure of both lamivudine and Tenofovir disoproxil fumarate rescue therapy

P. Angus, J. George, S. Locarnini, 2022 .

Washout of hepatocellular carcinoma on portal venous phase of multidetector computed tomography in a pre‐transplant population

Yu Xuan Kitzing, J. Kench, S. Strasser, 2015, Journal of medical imaging and radiation oncology.

Epidemiology, characteristics, and outcomes of patients with acute‐on‐chronic liver failure in Australia

K. Chan, G. McCaughan, S. Strasser, 2023, Journal of gastroenterology and hepatology.

Cadaveric liver transplant from older donors.

G. McCaughan, S. Strasser, D. Verran, 2008, Saudi medical journal.

Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection: an integrated analysis

O. Weiland, J. Dufour, S. Paik, 2017 .

High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis

R. Marinho, J. Dufour, P. Thuluvath, 2017 .

Surface antigen negative hepatitis B infection: the importance of screening before B cell‐depleting therapy

S. Strasser, Ken Liu, S. Mudaliar, 2019, The Medical journal of Australia.

Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-α (PROSPER): an observational study among 550 patients

A. Krag, M. Hudson, S. Strasser, 2018, Hepatology, Medicine and Policy.

BK nephropathy as a cause of renal dysfunction in an ABO-incompatible liver transplant patient.

S. Strasser, D. Gracey, A. Majumdar, 2020, Transplantation.

Drug‐induced liver injury in Australia, 2009–2020: the increasing proportion of non‐paracetamol cases linked with herbal and dietary supplements

G. McCaughan, S. Strasser, A. Majumdar, 2021, The Medical journal of Australia.

The dangers of herbal weight loss supplements: a case report of drug-induced liver injury secondary to Garcinia cambogia ingestion.

D. Bowen, S. Strasser, C. McKenzie, 2020, Pathology.

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants

V. Sundararajan, M. Sinclair, P. Revill, 2023, Hepatology communications.

Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of Differentiation Antibody Microarrays

R. Christopherson, L. Belov, G. McCaughan, 2015, Transplantation.

Is it safe to expand the indications for split liver transplantation in adults? A single‐center analysis of 155 in‐situ splits

C. Pulitano, R. K. Biswas, G. McCaughan, 2022, Clinical Transplantation.

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study

E. Gane, H. Dvory‐Sobol, D. Brainard, 2019, Journal of viral hepatitis.

Terlipressin therapy for moderate‐to‐severe hyponatraemia in patients with liver failure

D. Bowen, N. Shackel, S. Strasser, 2013, Internal medicine journal.

Cirrhosis of the liver in long-term marrow transplant survivors.

K. Sullivan, B. Storer, G. McDonald, 1999, Blood.

Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study

P. Gow, S. Bell, J. Lubel, 2016, Scandinavian journal of gastroenterology.

Hepatitis C: questions to be answered

S. Strasser, 1996, The Medical journal of Australia.

O66 SOFOSBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS

B. Conway, S. Zeuzem, G. Foster, 2014 .

Wide variation in pre-procedural blood product transfusion practices in cirrhosis: a national multidisciplinary survey

S. Bollipo, J. Lubel, S. Strasser, 2023, Hepatology communications.

Multivariable analysis of predictors to response to MMF according to treatment

A. Zekry, M. Weltman, G. McCaughan, 2019 .

International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.

D. Samuel, N. Terrault, P. Kwo, 2017, Transplantation.

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.

R. Marinho, J. Dufour, P. Thuluvath, 2018, Journal of hepatology.

High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection

P. Kwo, E. Gane, J. Kort, 2016 .

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

M. Manns, E. Schiff, K. Reddy, 2017, The New England journal of medicine.

A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis

P. Angus, E. Gane, G. McCaughan, 2008, Hepatology.

Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial

V. Mazzaferro, L. Bassaganyas, J. Bruix, 2017 .

De Novo Malignancies after Liver Transplantation

G. McCaughan, S. Strasser, A. Majumdar, 2021, Liver Transplantation.

Minimal but significant improvement in survival for non–hepatitis C–related adult liver transplant patients beyond the one‐year posttransplant mark

G. McCaughan, N. Shackel, S. Strasser, 2010, Liver transplantation.

Impact of Intensive Care Unit Discharge Delay on Liver Transplantation Outcomes

C. Pulitano, G. McCaughan, S. Strasser, 2022, Journal of clinical medicine.

Impact of intensive care unit discharge delay after medical clearance on outcomes after liver transplantation

C. Pulitano, G. McCaughan, S. Strasser, 2021 .

Increasing liver transplantation waiting list mortality: a report from the Australian National Liver Transplantation Unit, Sydney

G. McCaughan, R. Allen, N. Shackel, 2010, Internal medicine journal.

Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis—authors' reply

S. Strasser, S. Roberts, A. Nicoll, 2019, Alimentary pharmacology & therapeutics.